Lymph node micrometastases from breast carcinoma: Reviewing the dilemma

Cancer

Volumn 80, Issue 7, 1997, Pages 1188-1197

  Dowlatshahi, Kambiz ^a   Fan, Ming ^a   Snider, Howard C ^b   Habib, Fahim A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Baptist Medical Center   (United States)

Author keywords

Breast carcinoma; Lymph nodes; Micrometastases; Occult metastases

Indexed keywords

MONOCLONAL ANTIBODY;

BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER RECURRENCE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAMMOGRAPHY; OCCULT CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; PROGNOSIS;

EID: 0030885609     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19971001)80:7<1188::AID-CNCR2>3.0.CO;2-H     Document Type: Review

References (55)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. 1996. CA Cancer J Clin 1996;46:5-27.
2. Fisher B, Redmond C, Fisher ER. The contribution of recent NSABP clinical trials of primary breast cancer therapy to an understanding of tumor biology - an overview of findings. Cancer 1980;46:1009-25.
3. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, et al. Relation of number of positive axillary nodes to prognosis of patients with primary breast cancer; an NSABP update. Cancer 1983;52(9):1551-7.
4. Rosen PP, Saigo P, Braum DW Jr., Weathers E, Depalo A. Predictors of recurrence in Stage I (T1N1MO) breast carcinoma. Ann Surg 1981;193:15-25.
5. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339(8785):1-15.
6. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339(8785):71-85.
7. Fisher B, Dignam J, Mamounas EP, Constantino JP, Wickerham DL, Redmond C, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate and fluorouracil. J Clin Oncol 1996;14(7):1982-92.
8. Goldhirsch A, Castiglione M, Gelber RD. The International Breast Cancer Study Group. A single perioperative chemotherapy course for node-negative breast cancer: five year results of trial V. Monogr Natl Cancer Inst 1992;11:89-96.
9. NCI. Alert on node-negative breast cancer. Breast Cancer Res Treat 1988;12:3-5.
10. Fisher B, Redmond C. The National Surgical Adjuvant Breast and Bowel Project. Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. Monogr Natl Cancer Inst 1992;(11):105-16.
11. Ludwig Breast Cancer Study Group. Toxic effects of early adjuvant chemotherapy for breast cancer. Lancet 1983; 2(8349):542-4.
12. Wilkinson EJ, Hause L, Hoffman RG, Kuzma JF, Rothwell DJ, Donegan WL, et al. Occult axillary lymph node metastases in invasive breast carcinoma: characteristics of the primary tumor and significance of the metastases. Pathol Annu 1982;17(Pt 2):67-91.
13. Saphir O, Amromin GD. Obscure axillary lymph node metastases in carcinoma of the breast. Cancer 1948;1:238-41.
14. Pickren JW. Significance of occult metastases. A study of breast cancer. Cancer 1961;14:1266-71.
15. Huvos AG, Hutter R, Berg JW. Significance of axillary macrometastases and micrometastases in mammary cancer. Ann Surg 1971;173(1):44-6.
16. Attiyeh FF, Jensen M, Huvos AG, Fracchia A. Axillary micrometastases and macrometastases in carcinoma of the breast. Surg Gynecol Obset 1977;144(6):839-42.
17. Fisher ER, Swamidoss S, Lee CH, Rockette H, Redmond C, Fisher B. Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 1978;42:2025-31.
18. Fisher ER, Palekar A, Rockette H, Redmond C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project (Protocol #4) V. Significance of axillary nodal micro- and macrometastases. Cancer 1978; 42:2032-8.
19. Black RB, Roberts M, Stewart HJ, Prescott R, Cant EL, Sumerling MD, et al. The search for occult metastases in breast cancer: does it add to established staging methods? Aust N Z J Surg 1980;50(6):574-9.
20. Rosen PP, Saigo P, Weathers E, Fracchia AA, Kinne DW. Axillary micro- and macrometastases in breast cancer: prognostic significance of tumor size. Ann Surg 1981;194(5):585-91.
21. Rosen PP, Saigo P, Braun DW Jr., Beattie EJ Jr., Kinne DW. Occult axillary lymph node metastases from breast cancers with intramammary lymphatic tumor emboli. Am J Surg Parhol 1982;6(7):639-41.
22. Wells CA, Heryet A, Brochier J, Gatter KC, Mason DY. The immunohistochemical detection of axillary micrometastases in breast cancer. Br J Cancer 1984;50(2):193-7.
23. Sloane JP, Ormerod M, Imrie SF, Coonbes RC. The use of antisera to epithelial membrane antigen in detecting micrometastases in histological sections. Br J Cancer 1980;42(3):392-8.
24. Bussolati G, Gugliotta P, Morra I, Pietribiasi F, Berardengo E. The immunohistochemical detection of lymph node metastases from infiltrating lobular carcinoma of the breast. Br J Cancer 1986;54(4):631-6.
25. Trojani M, de Mascarel I, Bonichon F, Coindre JM, Delsol G. Micrometastases to axillary lymph nodes from carcinoma of the breast. Br J Cancer 1987;55(3):303-6.
26. Byrne J, Waldron R, McAvinchey D, Dervan P. The use of monoclonal antibodies for the histopathological detection of mammary axillary micrometastases. Eur J Surg Oncol 1987; 13(5):409-11.
27. Friedman S, Bertin F, Mouriesse H, Benchabat A, Genin J, Sarrazin D, et al. Importance of tumor cells in axillary node sinus margins (clandestine metastases) discovered by serial sectioning in operable breast cancer. Acta Oncol 1988; 27(5):483-7.
28. Berry N, Jones D, Marshall R, Smallwood J, Taylor I. Comparison of the detection of breast carcinoma metastases by routine histological diagnosis and by immunohistochemical staining. Eur Surg Res 1988;20(4):225-32.
29. Sedmak DD, Meineke T, Knechtges DS. Detection of metastatic breast carcinoma with monoclonal antibodies to cytokeratins. Arch Pathol Lab Med 1989;113:786-9.
30. Apostolikas N, Petraki C, Agnantis AG. The reliability of histologically negative axillary lymph nodes in breast cancer. Pathol Res Pract 1988;184:35-8.
31. Raymond WA, Leong A-Y. Immunoperoxidase staining in the detection of lymph node metastases in Stage 1 breast cancer. Pathology 1989;21:11-5.
32. International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancer. Lancet 1990; 335(8749):1565-8.
33. Neville AM, Price K, Gelber RD, Goldhirsch A. Axillary node micrometastases and breast cancer. Lancet 1991:337(8749): 1110.
34. Springall RJ, Rytina E, Millis RR. Incidence and significance of micrometastases in axillary lymph nodes detected by immunohistochemical techniques. J Pathol 1990;160:174A.
35. Galea MH, Athanassiou E, Bell J, Dilks B, Robertson JF, Elston CW, et al. Occult regional lymph node metastases from breast carcinoma. Immunohistochemical detection with antibodies CAM 5.2 and NCRC-11. J Pathol 1991;165(3):221-7.
36. Chen Z-L, Wen D-L, Coulson WF, Giuliano AE, Cochran AJ. Occult metastases in the axillary lymph nodes of patients with breast cancer node negative by clinical and histological examination and conventional histology. Dis Markers 1991; 9(5):239-48.
37. Byrne J, Horgan P, England SS, Callaghan J, Given HF. A preliminary report on the usefulness of monoclonal antibodies to CA 15-3 and MCA in the detection of micrometastases in axillary lymph nodes draining primary breast cancer. Eur J Surg 1992;28:658-60.
38. de Mascarel I, Binichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary node micrometastases assessed by two special techniques: re-evaluation with longer follow-up. Br J Cancer 1992;66(3):523-7.
39. Clayton F, Hopkins CL. Pathologic correlates of prognosis in lymph node positive breast carcinomas. Cancer 1993; 71(5):1780-90.
40. Hainsworth PJ, Tjandra J, Stillwell RG, Machet D, Henderson MA, Rennie GC, et al. Detection and significance of occult metastases in node-negative breast cancer. Br J Surg 1993; 80(4):459-63.
41. Elson CE, Kulfe D, Johnson WW. Immunohistochemical detection and significance of axillary lymph node micrometastases in breast carcinoma. Anal Quant Cytol Histol 1993;15(3):171-8.
42. Nasser IA, Lee A, Bosari S, Saganich R, Heatley G, Silverman ML. Occult axillary lymph node metastases in "node negative" breast carcinoma. Hum Pathol 1993;24(9):950-7.
43. McGuckin MA, Cummings MC, Walsh MD, Hohn BG, Bennett IC, Wright RG. Occult axillary node metastases in breast cancer: their detection and prognostic significance. Br J Cancer 1996;73(1):88-95.
44. Molland JG, Barraclough BH, Gebski V, Miliken J, Bilous M. Prognostic significance of c-erbB-2 oncogene in node-negative breast cancer. Aust N Z J Surg 1996;66(2):64-70.
45. Schoenfeld A, Luqmani Y, Smith D, O'Reilly S, Shousha S, Sinnett HD, et al. Detection of breast cancer micrometastases in axillary lymph nodes using polymerase chain reaction. Cancer Res 1994;54(11):2986-90.
46. Mori M, Momori K, Inoue H, Barnard GF, Tsuji K, Nanbara S, et al. Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1995;55(15):3417-20.
47. Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Am J Pathol 1996;148(2):649-56.
48. Trojani M, de Mascarel I, Coindre JM, Delsol G. Micrometastases to axillary lymph nodes from invasive lobular carcinoma of the breast: detection by immunohistochemistry and prognostic significance. Br J Cancer 1987;56:838-9.
49. Rosen PP, Saigo P, Braun DW, Weathers E, Kinne DW. Prognosis in stage II (T1N1M0) breast cancer. Ann Surg 1981; 194(5):576-84.
50. Morton D, Wen D-R, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127(4): 392-9.
51. Krag DN, Weaver D, Alex JC, Fairbank JT. Surgical resection and radiolocalization of sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993;2:335-9.
52. Giuliano AE, Kirgan D, Guenther JM. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391-401.
53. Giuliano AE, Dale P, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995;222(3):394-401.
54. Chadha M, Chabon AB, Friedmann P, Vikram B. Predictors of axillary lymph node metastases in patients with T1 breast cancer: a multivariate analysis. Cancer 1994;73:350-3.
55. Bland KI, Konstadoulakis MM, Vezeridis MP, Wanebo HJ. Oncogene protein coexpression: value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminates for breast carcinoma. Ann Surg 1996;221(6):706-20.